Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas.

Guadalajara H., Herreros D., De-La-Quintana P., Trebol J., Garcia-Arranz M., Garcia-Olmo D.

Clinical Trial with a reported sample of 24 on Autoimmune Research, published in Int J Colorectal Dis (2011) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Int J Colorectal Dis (2011)
Country
Germany
Reported sample size
24
Source database
PubMed
PMID
22065114
DOI
10.1007/s00384-011-1350-1

Abstract (original English)

In patients with perianal fistulas, administration of adult stem cells (ASCs) derived from liposuction samples has proved a promising technique in a preceding phase II trial. We aimed to extend follow-up of these patients with this retrospective study. Patients who had received at least one dose of treatment (ASCs plus fibrin glue or fibrin glue alone) were included. Adverse events notified since the end of the phase II study were recorded. Clinical and magnetic resonance imaging (MRI) criteria were used to determine whether recurrence of the healed fistula had occurred. Data were available for 21 out of 24 patients treated with ASCs plus fibrin glue and 13 out of 25 patients treated with fibrin glue in the phase II study. Follow-up lasted a mean of 38.0 and 42.6 months, respectively. Two adverse events unrelated to the original treatment were reported, one in each group. There were no reports of anal incontinence associated with the procedure. Of the 12 patients treated with ASCs plus fibrin glue who were included in the retrospective follow-up in the complete closure group, only 7 remained free of recurrence. MRI was done in 31 patients. No relationship was detected between MRI results and the clinical fistula status, independent of the treatment received. Long-term follow-up reaffirmed the very good safety profile of the treatment. Nevertheless, a low proportion of the stem

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Adipose TissueAdultAdult Stem CellsCrohn DiseaseFemaleFibrin Tissue AdhesiveFollow-Up StudiesHumansMagnetic Resonance ImagingMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research